Current Issues in Cancer Palliative care

Davis, Carol; Hardy, Jean François

doi:10.1136/bmj.308.6940.1359

Cited by 18 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was no limit on the number of drugs to be combined in the syringe driver in 66% of the palliative care services. The other services imposed a median limit of two drugs (range: [1][2][3][4] in combination. The services were asked for the average number of drugs prepared in combination in syringe drivers.…”

Section: Resultsmentioning

confidence: 99%

National survey of drug use in palliative care

et al. 1996

View full text Add to dashboard Cite

The objective was to compile data on therapeutic approaches employed in palliative care in Australia, including practices relating to combining drugs in syringe drivers for administration by subcutaneous infusion. A questionnaire, with a reply-paid envelope, was sent to 130 teaching hospitals and palliative care services throughout Australia. Ninety-six responses were received (74% response rate). Drugs commonly administered in palliative care included oral morphine (97% of respondents), subcutaneous morphine (76%), oral metoclopramide (82%), subcutaneous metoclopramide (41%), oral dexamethasone (70%), oral haloperidol (50%), subcutaneous haloperidol (43%), oral prochlorperazine (47%), oral codeine (38%) and subcutaneous midazolam (36%). Drugs frequently combined in syringe drivers for subcutaneous infusion included morphine plus metoclopramide (67%), morphine plus midazolam (66%), and all three of these drugs (35%). Only 48% of the palliative care services had a policy on combining drugs in syringe drivers for administration by subcutaneous infusion and 34% had an upper limit on the number of drugs combined in syringe drivers. Twenty-nine per cent of respondents had encountered problems (e.g. incompatibilities) when combining drugs in syringe drivers for administration by subcutaneous infusion. This study has revealed considerable variation in the practice of therapeutics and the combining of drugs in syringe drivers for administration by subcutaneous infusion in palliative care.

show abstract

Section: Resultsmentioning

confidence: 99%

National survey of drug use in palliative care

et al. 1996

View full text Add to dashboard Cite

show abstract

“…24 Unfortunately, the debate over its evidence remains, with conflicting views in the literature and prescribers often following their own individual preferences. Corticosteroids are an alternative treatment for anorexia and fatigue, 25 but their effect is usually temporary and often subsides after about 4 weeks. Corticosteroids may be the treatment of choice in less ambulatory patients who have a short life expectancy, although they also have an accepted role in antitumour treatment effects.…”

Section: Gastrointestinal Symptomsmentioning

confidence: 99%

Prostate cancer: palliative care and pain relief

Kaya

Feuer

2004

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

“…Cancer patients often present with multiple pains, each of which has a different aetiology (Walsh & West, 1988). addition, pain is recognized as comprising physical, psychological, social and spiritual lmensions (Davis & Hardy, 1994). Therefore, a multidimensional assessment is required in order to identdy what types of pain the patient is experiencing, the causes of pain and the factors that might be influencing a patients' perception of pain.…”

Section: Painmentioning

confidence: 99%

Advances in supportive care

Redmond

1996

Eur J Cancer Care

View full text Add to dashboard Cite

A range of distressing symptoms, such as nausea and vomiting, dyspnoea and pain, which invariably impair quality of life, may develop in cancer patients as a result of their disease and treatment. The side-effects of cancer treatments place additional burdens on the patient. Patients indicate that they find nausea and vomiting and fatigue to be the most distressing symptoms. The burden of distressing symptoms and the side-effects of cancer treatments may be so great for some patients that they make a decision not to continue with treatment. Developing better methods of managing these complaints is critical for improving both quality of life and treatment outcome. Over the past two decades there have been dramatic advances in supportive care. The most significant advances have occurred in the general approach to symptom management and in the development of new pharmacological agents. Advances have also occurred in non-pharmacological approaches to supportive care and it is now acknowledged that interventions such as patient education and complementary therapies have an important role to play in ameliorating distressing symptoms.

show abstract

Current Issues in Cancer Palliative care

Cited by 18 publications

References 31 publications

National survey of drug use in palliative care

National survey of drug use in palliative care

Prostate cancer: palliative care and pain relief

Advances in supportive care

Contact Info

Product

Resources

About